IL33 and neoplasm: Interestingly, we showed the inducible expression of immune checkpoint molecule PD-1 on effector CD8+ T cells and elevated levels of PD-L1 on tumor cells by IL-33 treatment, thereby providing a strong rationale for combination therapy of IL-33 and immune checkpoint blockade (ICB).